Lilly, however, noted that a pre-specified secondary analysis of pooleddata showed statistically significant slowing of cognitive decline in patients with mild-to-moderate disease who were treated with its solanezumab compound.
And pre-specified secondary subgroup analyses of pooleddata across both studies showed a statistically significant slowing of cognitive decline in patients with mild disease, but not in those with moderate disease.